Identification of Genetic Mutations in Human Lung Cancer by Targeted Sequencing

Citations Over TimeTop 16% of 2015 papers

Abstract

Lung cancer remains the most prevalent malignancy and the primary cause of cancer-related deaths worldwide. Unique mutations patterns can be found in lung cancer subtypes, in individual cancers, or within a single tumor, and drugs that target these genetic mutations and signal transduction pathways are often beneficial to patients. In this study, we used the Ion Torrent AmpliSeq Cancer Panel to sequence 737 loci from 45 cancer-related genes and oncogenes to identify genetic mutations in 48 formalin-fixed, paraffin-embedded (FFPE) human lung cancer samples from Chinese patients. We found frequent mutations in EGFR, KRAS, PIK3CA, and TP53 genes. Moreover, we observed that a portion of the lung cancer samples harbored two or more mutations in these key genes. This study demonstrates the feasibility of using the Ion Torrent sequencing to efficiently identify genetic mutations in individual tumors for targeted lung cancer therapy.

Related Papers

• → Targeting the KRAS Pathway in Non-Small Cell Lung Cancer(2016)133 cited
• → KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing(2023)93 cited
• → Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner(2022)14 cited
• → Application of panel for Ion Torrent PGM sequencing of genetic disease(2016)
• → Research progress of KRAS-targeted therapy for pancreatic ductal adenocarcinama(2018)